(RTTNews) - Predictive Oncology Inc. (POAI) on Tuesday announced significant progress in its drug repurposing initiative using artificial intelligence or AI.
The company successfully identified several previously abandoned or discontinued drugs with potential for repurposing in the treatment of ovarian, colon, and breast cancers.
Utilizing its proprietary AI platform and biobank of primary tumor samples, Predictive identified promising candidates, including Akt Inhibitors, Aurora A Inhibitors, and PARP1/2 Inhibitors, for further testing.
Early results showed that these drugs, after just eight weeks of analysis, outperformed a known standard of care drug for colon cancer, showing the potential to expedite the development of new cancer therapies.
Raymond Vennare, CEO of Predictive Oncology, expressed, "We are encouraged by the outcome of our AI-driven repurposing efforts and are confident that these findings will lead to meaningful collaborations with major pharmaceutical companies to further develop these promising drug candidates."
The company aims to continue utilizing its AI platform to repurpose approved and abandoned drugs for other indications, potentially offering faster, more cost-effective treatments for cancer patients.
Currently, POAI is trading at $1.67 up by 3.12%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
